Abecma (idecabtagene vicleucel) for relapsed or refractory multiple myeloma
Customize your policy alerts
Sign up for harvard pilgrim health care Policy 6763659 alerts
Get alerted when Policy 6763659 changes without checking for updates manually.
Monitor payer policy activity
This policy governs coverage and prior authorization for Abecma, a CAR T-cell therapy, for eligible commercial and specified public-plan members with relapsed or refractory multiple myeloma. It applies to providers requesting treatment in either inpatient or outpatient settings.
No material clinical or coverage changes in this revision.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.